Yousef George M, Diamandis Eleftherios P
Department of Pathology and Laboratory Medicine, Mount Sinai Hospital, Toronto, Ontario, Canada.
Thromb Haemost. 2003 Jul;90(1):7-16.
Serine proteases are proteolytic enzymes with an active serine residue in their catalytic site. Kallikreins are a subgroup of the serine protease family and are known to have diverse physiological functions. The human tissue kallikrein gene family has now been fully characterized and includes 15 members, clustered in a 300 kb region on chromosome 19q13.4. In this review, we discuss the common structural features of kallikreins at the DNA, mRNA and protein levels. Kallikreins are secreted as inactive zymogens and are activated by cleavage of an N-terminal peptide. Some kallikreins can undergo autoactivation while others may be activated by other kallikreins or other proteases. Most kallikreins are predicted to have trypsin-like enzymatic activity except for three members which may have chymotrypsin-like activity. Circumstantial evidence suggests that at least some kallikreins may be part of an enzymatic cascade pathway which is activated in aggressive forms of ovarian and probably other cancers. Accumulating evidence suggests potential diagnostic and/or prognostic roles of kallikreins in diverse malignancies. In addition to PSA, many other kallikreins show differential expression in malignancy. For example, hK6, 10 and 11 are promising serological markers for ovarian cancer diagnosis. KLK10 may act as a tumor suppressor. In addition to their diagnostic and prognostic values, kallikreins may also be good therapeutic targets.
丝氨酸蛋白酶是一类在催化位点含有活性丝氨酸残基的蛋白水解酶。激肽释放酶是丝氨酸蛋白酶家族的一个亚群,已知具有多种生理功能。人类组织激肽释放酶基因家族现已得到充分表征,包括15个成员,聚集在19号染色体19q13.4上的一个300 kb区域。在这篇综述中,我们讨论了激肽释放酶在DNA、mRNA和蛋白质水平上的共同结构特征。激肽释放酶以无活性的酶原形式分泌,并通过N端肽的切割而被激活。一些激肽释放酶可进行自身激活,而其他激肽释放酶可能被其他激肽释放酶或其他蛋白酶激活。除了三个可能具有胰凝乳蛋白酶样活性的成员外,大多数激肽释放酶预计具有胰蛋白酶样酶活性。间接证据表明,至少一些激肽释放酶可能是在侵袭性卵巢癌以及可能的其他癌症中被激活的酶促级联途径的一部分。越来越多的证据表明激肽释放酶在多种恶性肿瘤中具有潜在的诊断和/或预后作用。除了前列腺特异性抗原(PSA)外,许多其他激肽释放酶在恶性肿瘤中表现出差异表达。例如,hK6、10和11是卵巢癌诊断有前景的血清学标志物。KLK10可能起肿瘤抑制作用。除了它们的诊断和预后价值外,激肽释放酶也可能是良好的治疗靶点。